Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Phase 3

Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

NCT04246047 · tracked via the Priya Life Science Poland tracker
Phase
Phase 3
Started
2020-05-07
Last updated
2026-11-13

Condition(s) studied

Multiple Myeloma

Investigational drug(s) / intervention(s)

Belantamab mafodotin →Daratumumab →Bortezomib →Dexamethasone →

Belantamab mafodotin: Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate

Daratumumab: Anti-cluster of differentiation 38 \[CD-38\] monoclonal antibody

Bortezomib: Proteasome Inhibitor

Dexamethasone: Synthetic glucocorticoid with anti-tumor activity

Study summary

This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Confirmed diagnosis of multiple myeloma as defined by the International Myeloma Working Group (IMWG) criteria. * Previously treated with at least 1 prior line of multiple myeloma (MM) therapy, and must have documented disease progression during or after their most recent therapy. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. * Must have at least 1 aspect of measurable disease, defined as one of the following; 1. Urine M-protein excretion \>=200 mg per 24-hour, or 2. Serum M-protein concentration \>=0.5 grams per deciliter (g/dL), or 3. Serum free light chain (FLC) assay: involved FLC level \>=10 mg per dL (\>=100 mg per liter) and an abnormal serum free light chain ratio (\<0.26 or \>1.65). * All prior treatment-related toxicities (defined by National Cancer Institute Common Toxicity Criteria for Adverse Events \[NCI-CTCAE\] version 5.0) must be \<=Grade 1 at the time of enrollment, except for alopecia. * Adequate organ function Exclusion Criteria: * Intolerant to daratumumab. * Refractory to daratumumab or any other anti-CD38 therapy (defined as progressive disease during treatment with anti-CD38 therapy, or within 60 days of completing that treatment). * Intolerant to bortezomib, or refractory to bortezomib (defined as progressive disease during treatment with a bortezomib-containing regimen of 1.3 mg/m\^2 twice weekly, or within 60 days of completing that treatment). Note: participants with progressive disease during treatment with a weekly bortezomib regimen are allowed. * Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain. * Prior treatment with anti-B-cell maturation antigen (anti-BCMA) therapy. * Prior allogenic stem cell transplant. * Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions, including renal, liver, cardiovascular, or certain prior malignancies. * Corneal epithelial disease.

Primary outcome measure(s)

  • Progression-free Survival (PFS) — Up to approximately 41 months
    PFS is defined as time from randomization until earliest date of disease progression (PD), determined by Independent Review Committee (IRC), according to the International Myeloma Working Group (IMWG) Response Criteria, or death due to any cause. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5 grams per deciliter {g/dL}\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200 milligrams per 24 hours {mg/24h}\]; participants without measurable serum \& urine M-protein levels, difference between involved \& uninvolved serum free light chains (sFLC) levels \[absolute increase \>10mg/dL\]; appearance of new lesion,\>=50% increase from nadir in Sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1 centimeter (cm) in short axis.

Trial sites (143)

FacilityCityRegionStatus
GSK Investigational Site Yuma Arizona
GSK Investigational Site Mission Kansas
GSK Investigational Site Denver North Carolina
GSK Investigational Site Blue Ash Ohio
GSK Investigational Site Tyler Texas
GSK Investigational Site Roanoke Virginia
GSK Investigational Site Camperdown New South Wales
GSK Investigational Site Liverpool New South Wales
GSK Investigational Site Newcastle New South Wales
GSK Investigational Site St Leonards New South Wales
GSK Investigational Site Wollongong New South Wales
GSK Investigational Site Benowa Queensland
GSK Investigational Site Herston Queensland
GSK Investigational Site Ashford South Australia
GSK Investigational Site Box Hill Victoria
GSK Investigational Site Heidelberg Victoria
GSK Investigational Site Melbourne Victoria
GSK Investigational Site Murdoch Western Australia
GSK Investigational Site Nedlands Western Australia
GSK Investigational Site Jette Brussels Capital
GSK Investigational Site Woluwé-Saint-Lambert Brussels Capital
GSK Investigational Site Ghent Oost-Vlaanderen
GSK Investigational Site Roeselare Belgium
GSK Investigational Site Porto Alegre Rio Grande do Sul
GSK Investigational Site Florianópolis Santa Catarina
GSK Investigational Site Joinville Brazil
GSK Investigational Site Natal Brazil
GSK Investigational Site Rio de Janeiro Brazil
GSK Investigational Site São Paulo Brazil
GSK Investigational Site São Paulo Brazil
GSK Investigational Site Edmonton Alberta
GSK Investigational Site London Ontario
GSK Investigational Site Toronto Ontario
GSK Investigational Site Montreal Quebec
GSK Investigational Site Beijing China
GSK Investigational Site Beijing China
GSK Investigational Site Changchun China
GSK Investigational Site Guangzhou China
GSK Investigational Site Guangzhou China
GSK Investigational Site Hangzhou China

+ 103 more sites — see the full list on the official registry below.

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04246047 on ClinicalTrials.gov ↗ ← All trials in Poland